Cathie Wood's ARK ETFs made notable trades on Wednesday, October 16, 2024, with the largest dollar-value transaction being the sale of Moderna Inc (NASDAQ:MRNA) shares. ARK's ETFs offloaded a substantial 46,186 shares of the biotechnology company, indicating a move away from one of the leading names in mRNA technology. The sale was split between the ARKK ETF, which sold 35,103 shares, and the ARKG ETF, which parted with 11,083 shares, totaling approximately $2.65 million.
In contrast, ARK showed increasing confidence in the gene-editing sector by purchasing 43,669 shares of Intellia Therapeutics Inc (NASDAQ:NTLA), valued at around $852,418. The ARKK ETF acquired the majority with 35,744 shares, while the ARKG ETF added 7,925 shares to its holdings. This move suggests a bullish stance on the company's CRISPR technology and its potential for therapeutic applications.
Another significant investment was made in Tempus AI Inc (NASDAQ:TEM), with ARK buying 11,112 shares across its ARKK and ARKG ETFs for a total value of $518,152. This follows a trend, as just the day before, ARK had invested heavily in Tempus AI, highlighting a pattern of accumulation in the artificial intelligence-driven biotech firm.
The ARK ETFs also adjusted their positions in other companies. ARK sold 23,473 shares of Block Inc (NYSE:SQ), the financial services and mobile payment company, for approximately $1.69 million. This divestiture was conducted entirely through the ARKK ETF.
Further sales included 2,636 shares of Robinhood Markets Inc (NASDAQ:HOOD) for around $70,644 and 7,649 shares of Markforged Holding Corp (NYSE:MKFG) totaling approximately $35,032. These transactions were spread across the ARKW, ARKQ, and ARKX ETFs. ARK also reduced its holdings in Materialise NV (NASDAQ:MTLS) by selling 3,100 shares, valued at $15,779.
On the buying side, ARK continued to show interest in Blade Air Mobility Inc (NASDAQ:BLDE), a company focused on urban air mobility, by acquiring 400 shares distributed between the ARKQ and ARKX ETFs for a modest $1,380. This follows a pattern of consistent buying in the company over the past week.
Overall, the day's trades reflect a strategic rebalancing of ARK's ETF portfolios, with a clear focus on innovative companies in the gene-editing and AI sectors. Investors following Cathie Wood's ARK ETFs will be watching these trends closely as they develop further.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.